Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer

Cancer Letters

Volumn 185, Issue 2, 2002, Pages 191-199

  Jarrard, David F ^a   Modder, Joshua ^a   Fadden, Paul ^a   Fu, Vivian ^a   Sebree, Linda ^a   Heisey, Dennis ^a   Schwarze, Steven R ^a   Friedl, Andreas ^a  

^a University of Wisconsin Health   (United States)

Author keywords

p16; pRb; Prostate cancer; Senescence

Indexed keywords

PROTEIN; PROTEIN P16; PROTEIN PRB; UNCLASSIFIED DRUG; PROTEIN P16INK4A; RETINOBLASTOMA PROTEIN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TREATMENT FAILURE; ADENOCARCINOMA; CELL CYCLE G1 PHASE; CHEMISTRY; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; G1 PHASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, RETINOBLASTOMA; HUMAN; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEIN P16; RETINOBLASTOMA PROTEIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; MIDDLE AGED;

EID: 0037191509     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00282-3     Document Type: Article

References (42)

1. Aging and cancer: The double-edged sword of replicative senescence
2. Replicative senescence: Implications for in vivo aging and tumor suppression: A review
3. P16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells
4. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells
5. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts
6. The p16/CDKN2 tumor suppressor gene and its relatives
7. Overcoming cellular senescence in human cancer pathogenesis
8. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells
9. A role for both RB and p53 in the regulation of human cellular senescence
10. Retinoblastoma protein family in cell cycle and cancer: A review
11. G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma
12. Deletional, mutational and methylation analyzes of CDKN2 in primary and metastatic prostate cancer
13. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas
14. P53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate
15. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma
16. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer
17. The checkerboard tissue block. An improved multitissue control block
18. The multitumor (sausage) tissue block: Novel method for immunohistochemical antibody testing
19. The immunohistochemical diagnostic panel for epithelial mesothelioma: A reevaluation after heat-induced epitope retrieval
20. Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histopathological parameters
21. Histologic grading of prostate cancer: A perspective
22. The biology of replicative senescence
23. Genetic alterations in untreated metastases and androgen- independent prostate cancer detected by comparative genomic hybridization and allelotyping
24. Deletional, mutational, and methylation analyzes of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer
25. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis
26. Overexpression of the cell cycle inhibitor p16INK4 A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients
27. P16 mutations/deletions are not frequent events in prostate cancer
28. Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer
29. Biochemical characterization of p16
30. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2
31. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus
32. Interaction between Cdc37 and Cdk4 in human cells
33. Cdc37 promotes the stability of protein kinases Cdc28 and Cak1
34. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia
35. Expression of retinoblastoma gene (Rb) protein in T12M0 prostatic adenocarcinoma
36. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas
37. Loss of p16(INK4) protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression
38. Human glioblastomas with no alterations of the CDKN2 A (p16INK4 A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene
39. Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation
40. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
41. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: Implications for carcinogenesis, senescence, and age-related diseases
42. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor